biostudies-literatureKim MInnovative Medicines InitiativeSteno Diabetes Center Copenhagen (SDCC)Fifth Framework ProgrammeMedical Research CouncilSeventh Framework ProgrammeEFPIANational Institutes of HealthEuropean CommissionBasque GovernmentNIGMS NIH HHSNovartis817-827https://www.ebi.ac.uk/biostudies/studies/S-EPMC6849698biostudies-literatureUnknown15(6)<h4>Introduction</h4>A critical and as-yet unmet need in Alzheimer's disease (AD) is the discovery of peripheral small molecule biomarkers. Given that brain pathology precedes clinical symptom onset, we set out to test whether metabolites in blood associated with pathology as indexed by cerebrospinal fluid (CSF) AD biomarkers.<h4>Methods</h4>This study analyzed 593 plasma samples selected from the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery study, of individuals who were cognitively healthy (n = 242), had mild cognitive impairment (n = 236), or had AD-type dementia (n = 115). Logistic regressions were carried out between plasma metabolites (n = 883) and CSF markers, magnetic resonance imaging, cognition, and clinical diagnosis.<h4>Results</h4>Eight metabolites were associated with amyloid β and one with t-tau in CSF, these were primary fatty acid amides (PFAMs), lipokines, and amino acids. From these, PFAMs, glutamate, and aspartate also associated with hippocampal volume and memory.<h4>Discussion</h4>PFAMs have been found increased and associated with amyloid β burden in CSF and clinical measures.Alzheimer's & dementia : the journal of the Alzheimer's AssociationPrimary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort.PMC6849698R15 GM107864MC_PC_17215FP7/2007‐201337670R15-GM107864QLRT‐2001‐2455R15‐GM107864UKDRI-1003SDCC 3.C. Sys MedFrolich LScheltens PStreffer JSuvitaival TAhmad TAshton NZetterberg HNevado-Holgado ABos IFrisoni GBBordet RVos SPopp JMolinuevo JLFreund-Levi YRichardson JLegido-Quigley CGabel SMerkler DJDe Roeck ELleo ASnowden SMartinez-Lage PBlin OBlennow KProitsi PSleegers KWallin AEngelborghs SLovestone SBarkhof FKim MTeunissen CJohannsen PAli AHye ATainta MDobricic VRami LBaird APeyratout GSala IBertram LKettunen PVandenberghe RMeersmans KTsolaki MVerhey FVisser PJTen Kate MWestwood SfalsePrimary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort.<h4>Introduction</h4>A critical and as-yet unmet need in Alzheimer's disease (AD) is the discovery of peripheral small molecule biomarkers. Given that brain pathology precedes clinical symptom onset, we set out to test whether metabolites in blood associated with pathology as indexed by cerebrospinal fluid (CSF) AD biomarkers.<h4>Methods</h4>This study analyzed 593 plasma samples selected from the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery study, of individuals who were cognitively healthy (n = 242), had mild cognitive impairment (n = 236), or had AD-type dementia (n = 115). Logistic regressions were carried out between plasma metabolites (n = 883) and CSF markers, magnetic resonance imaging, cognition, and clinical diagnosis.<h4>Results</h4>Eight metabolites were associated with amyloid β and one with t-tau in CSF, these were primary fatty acid amides (PFAMs), lipokines, and amino acids. From these, PFAMs, glutamate, and aspartate also associated with hippocampal volume and memory.<h4>Discussion</h4>PFAMs have been found increased and associated with amyloid β burden in CSF and clinical measures.2019-01-01T00:00:00Z2019 Jun2024-12-04T06:23:47.334Z2020-05-21T15:48:55ZS-EPMC68496983107843310.1016/j.jalz.2019.03.004